Status:
ACTIVE_NOT_RECRUITING
MHealth Incentivized Adherence Plus Patient Navigation
Lead Sponsor:
University of Washington
Collaborating Sponsors:
National Institute on Drug Abuse (NIDA)
Conditions:
Opioid Use Disorder
Medication Adherence
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Polysubstance use involving opioids and methamphetamine is emerging as a new public health crisis. Patients with opioids and methamphetamine use often experience serious medical complications requirin...
Eligibility Criteria
Inclusion
- Adult greater than or equal to 18 years of age
- Admitted to Harborview Medical Center (HMC) on any inpatient service
- Initiated on buprenorphine for OUD while in the hospital or at the time of discharge and planning to continue outpatient
- Used methamphetamine within the past 30 days (any route of administration or frequency)
- Willing to be randomized to video-DOT
- Willing and able to use a smartphone (study can provide) and work with patient navigator
- Discharge setting does not preclude the use of video-DOT (i.e., nursing home, inpatient psychiatry, etc.)
Exclusion
- Unable or unwilling to use smartphone (phones to be provided when needed)
- Cognitive impairment (acute or chronic) resulting in inability to provide informed consent
- Currently incarcerated and will discharge to jail or prison
- Plans to discontinue buprenorphine in the near future (\<3 months)
- Lives far away such that cannot keep study visit at 30 days post-discharge
- Not English speaking
- Behavioral risk per discretion of research staff
Key Trial Info
Start Date :
January 3 2024
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 22 2026
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT06027814
Start Date
January 3 2024
End Date
September 22 2026
Last Update
December 18 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Harborview Medical Center
Seattle, Washington, United States, 98104